LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 5 von insgesamt 5

Suchoptionen

  1. Artikel ; Online: Persistent SARS-CoV-2 Alpha Variant Infection in Immunosuppressed Patient, France, February 2022.

    Fourati, Slim / Gautier, Guillaume / Chovelon, Myriam / Soulier, Alexandre / N'Debi, Melissa / Demontant, Vanessa / Kennel, Céline / Rodriguez, Christophe / Pawlotsky, Jean-Michel

    Emerging infectious diseases

    2022  Band 28, Heft 7, Seite(n) 1512–1515

    Abstract: We describe persistent circulation of SARS-CoV-2 Alpha variant in an immunosuppressed patient in France during February 2022. The virus had a new pattern of mutation accumulation. The ongoing circulation of previous variants of concern could lead to ... ...

    Abstract We describe persistent circulation of SARS-CoV-2 Alpha variant in an immunosuppressed patient in France during February 2022. The virus had a new pattern of mutation accumulation. The ongoing circulation of previous variants of concern could lead to reemergence of variants with the potential to propagate future waves of infection.
    Mesh-Begriff(e) COVID-19 ; France/epidemiology ; Humans ; SARS-CoV-2/genetics
    Sprache Englisch
    Erscheinungsdatum 2022-05-06
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1380686-5
    ISSN 1080-6059 ; 1080-6040
    ISSN (online) 1080-6059
    ISSN 1080-6040
    DOI 10.3201/eid2807.220467
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.

    Leleu, Xavier / Hulin, Cyrille / Lambert, Jerome / Bobin, Arthur / Perrot, Aurore / Karlin, Lionel / Roussel, Murielle / Montes, Lydia / Cherel, Brieuc / Chalopin, Thomas / Slama, Borhane / Chretien, Marie-Lorraine / Laribi, Kamel / Dingremont, Claire / Roul, Christophe / Mariette, Clara / Rigaudeau, Sophie / Calmettes, Claire / Dib, Mamoun /
    Tiab, Mourad / Vincent, Laure / Delaunay, Jacques / Santagostino, Alberto / Macro, Margaret / Bourgeois, Emmanuelle / Orsini-Piocelle, Frederique / Gay, Julie / Bareau, Benoit / Bigot, Noemie / Vergez, François / Lebreton, Pierre / Tabrizi, Reza / Waultier-Rascalou, Agathe / Frenzel, Laurent / Le Calloch, Ronan / Chalayer, Emilie / Braun, Thorsten / Lachenal, Florence / Corm, Selim / Kennel, Celine / Belkhir, Rakiba / Bladé, Jean-Sebastien / Joly, Bertrand / Richez-Olivier, Valentine / Gardeney, Helene / Demarquette, Helene / Robu-Cretu, Daniela / Garderet, Laurent / Newinger-Porte, Muriel / Kasmi, Amine / Royer, Bruno / Decaux, Olivier / Arnulf, Bertrand / Belhadj, Karim / Touzeau, Cyrille / Mohty, Mohamad / Manier, Salomon / Moreau, Philippe / Avet-Loiseau, Hervé / Corre, Jill / Facon, Thierry

    Nature medicine

    2024  

    Abstract: CD38-targeting immunotherapy is approved in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM) that are transplant ineligible (TI) and is considered the best standard of care (SOC). To improve current ...

    Abstract CD38-targeting immunotherapy is approved in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM) that are transplant ineligible (TI) and is considered the best standard of care (SOC). To improve current SOC, we evaluated the added value of weekly bortezomib (V) to isatuximab plus lenalidomide and dexamethasone (IsaRd versus Isa-VRd). This Intergroupe Francophone of Myeloma phase 3 study randomized 270 patients with NDMM that were TI, aged 65-79 years, to IsaRd versus Isa-VRd arms. The primary endpoint was a minimal residual disease (MRD) negativity rate at 10
    Sprache Englisch
    Erscheinungsdatum 2024-06-03
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 1220066-9
    ISSN 1546-170X ; 1078-8956
    ISSN (online) 1546-170X
    ISSN 1078-8956
    DOI 10.1038/s41591-024-03050-2
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel: Potential side effect of propofol and sevoflurane for anesthesia of anti-NMDA-R encephalitis.

    Lapébie, François-Xavier / Kennel, Céline / Magy, Laurent / Projetti, Fabrice / Honnorat, Jérôme / Pichon, Nicolas / Vignon, Philippe / François, Bruno

    BMC anesthesiology

    2014  Band 14, Seite(n) 5

    Abstract: Background: Many anesthetic drugs interact with the NMDA receptor and may therefore alter the clinical presentation of anti-NMDA-R encephalitis.: Case presentation: A 24-year-old woman was admitted to hospital for decreased consciousness and ... ...

    Abstract Background: Many anesthetic drugs interact with the NMDA receptor and may therefore alter the clinical presentation of anti-NMDA-R encephalitis.
    Case presentation: A 24-year-old woman was admitted to hospital for decreased consciousness and hyperthermia. Cerebrospinal fluid analysis revealed lymphocytic pleocytosis, and elevated protein. Cultures were negative. Patient state worsened with agitation, facial dyskinesia, ocular deviation, and limb dystonia. Diagnosis of anti-NMDA-R encephalitis was evidenced by specific antibodies. High doses of methylprednisolone were administered. CT scan disclosed an ovarian teratoma and tumor resection was scheduled under anesthesia with propofol, sufentanil, atracurium and sevoflurane. Sedation after surgery was maintained with propofol. Rapidly after surgery, patient's condition deteriorated with increase of dyskinesias, and two tonic-clonic generalized seizure events.
    Conclusion: In patients with anti-NMDA-R encephalitis, anesthesia using benzodiazepines, opiates and curares, which fail to interfere with the NMDA pathway, should be preferred.
    Mesh-Begriff(e) Anesthesia/adverse effects ; Anesthesia/methods ; Anesthetics, Inhalation ; Anesthetics, Intravenous ; Anti-N-Methyl-D-Aspartate Receptor Encephalitis/complications ; Anti-N-Methyl-D-Aspartate Receptor Encephalitis/diagnosis ; Anti-N-Methyl-D-Aspartate Receptor Encephalitis/therapy ; Drug Therapy, Combination/adverse effects ; Dyskinesia, Drug-Induced/complications ; Dyskinesia, Drug-Induced/diagnosis ; Female ; Humans ; Methyl Ethers/administration & dosage ; Methyl Ethers/adverse effects ; Propofol/administration & dosage ; Propofol/adverse effects ; Sevoflurane ; Young Adult
    Chemische Substanzen Anesthetics, Inhalation ; Anesthetics, Intravenous ; Methyl Ethers ; Sevoflurane (38LVP0K73A) ; Propofol (YI7VU623SF)
    Sprache Englisch
    Erscheinungsdatum 2014-01-16
    Erscheinungsland England
    Dokumenttyp Case Reports ; Journal Article
    ISSN 1471-2253
    ISSN 1471-2253
    DOI 10.1186/1471-2253-14-5
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Facial purpura associated with Capnocytophaga canimorsus septicaemia; role of sunlight?

    Kennel, Céline / Barraud, Olivier / Lapebie, François-Xavier / Sparsa, Agnes / Duvoid, Tiffany / Chapellas, Catherine / Hidri, Nadia / Francois, Bruno

    European journal of dermatology : EJD

    2013  Band 23, Heft 3, Seite(n) 427–428

    Mesh-Begriff(e) Capnocytophaga ; Facial Dermatoses/microbiology ; Gram-Negative Bacterial Infections/etiology ; Humans ; Male ; Middle Aged ; Purpura Fulminans/microbiology ; Sepsis/etiology ; Sunlight/adverse effects
    Sprache Englisch
    Erscheinungsdatum 2013-05
    Erscheinungsland France
    Dokumenttyp Case Reports ; Letter
    ZDB-ID 1128666-0
    ISSN 1952-4013 ; 1167-1122
    ISSN (online) 1952-4013
    ISSN 1167-1122
    DOI 10.1684/ejd.2013.2032
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel ; Online: Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML.

    Alleg, Manel / Solis, Morgane / Baloglu, Seyyid / Cotton, François / Kerschen, Philippe / Bourre, Bertrand / Ahle, Guido / Pruvo, Jean-Pierre / Leclerc, Xavier / Vermersch, Patrick / Papeix, Caroline / Maillart, Élisabeth / Houillier, Caroline / Chabrot, Cécile Moluçon / Claise, Béatrice / Malak, Sandra / Martin-Blondel, Guillaume / Bonneville, Fabrice / Caulier, Alexis /
    Marolleau, Jean-Pierre / Bonnefoy, Jérôme Tamburini / Agape, Philippe / Kennel, Céline / Roussel, Xavier / Chauchet, Adrien / De Seze, Jérôme / Fafi-Kremer, Samira / Kremer, Stéphane

    European radiology

    2020  Band 31, Heft 5, Seite(n) 2944–2955

    Abstract: Objectives: To compare brain MRI findings in progressive multifocal leukoencephalopathy (PML) associated to rituximab and natalizumab treatments and HIV infection.: Materials and methods: In this retrospective, multicentric study, we analyzed brain ... ...

    Abstract Objectives: To compare brain MRI findings in progressive multifocal leukoencephalopathy (PML) associated to rituximab and natalizumab treatments and HIV infection.
    Materials and methods: In this retrospective, multicentric study, we analyzed brain MRI exams from 72 patients diagnosed with definite PML: 32 after natalizumab treatment, 20 after rituximab treatment, and 20 HIV patients. We compared T2- or FLAIR-weighted images, diffusion-weighted images, T2*-weighted images, and contrast enhancement features, as well as lesion distribution, especially gray matter involvement.
    Results: The three PML entities affect U-fibers associated with low signal intensities on T2*-weighted sequences. Natalizumab-associated PML showed a punctuate microcystic appearance in or in the vicinity of the main PML lesions, a potential involvement of the cortex, and contrast enhancement. HIV and rituximab-associated PML showed only mild contrast enhancement, punctuate appearance, and cortical involvement. The CD4/CD8 ratio showed a trend to be higher in the natalizumab group, possibly mirroring a more efficient immune response.
    Conclusion: Imaging features of rituximab-associated PML are different from those of natalizumab-associated PML and are closer to those observed in HIV-associated PML.
    Key points: • Nowadays, PML is emerging as a complication of new effective therapies based on monoclonal antibodies. • Natalizumab-associated PML shows more inflammatory signs, a perivascular distribution "the milky way," and more cortex involvement than rituximab- and HIV-associated PML. • MRI differences are probably related to higher levels of immunosuppression in HIV patients and those under rituximab therapy.
    Mesh-Begriff(e) Brain/diagnostic imaging ; HIV Infections/complications ; HIV Infections/drug therapy ; Humans ; Leukoencephalopathy, Progressive Multifocal/chemically induced ; Leukoencephalopathy, Progressive Multifocal/diagnostic imaging ; Magnetic Resonance Imaging ; Natalizumab/adverse effects ; Retrospective Studies ; Rituximab/adverse effects
    Chemische Substanzen Natalizumab ; Rituximab (4F4X42SYQ6)
    Schlagwörter covid19
    Sprache Englisch
    Erscheinungsdatum 2020-11-06
    Erscheinungsland Germany
    Dokumenttyp Journal Article
    ZDB-ID 1085366-2
    ISSN 1432-1084 ; 0938-7994 ; 1613-3749
    ISSN (online) 1432-1084
    ISSN 0938-7994 ; 1613-3749
    DOI 10.1007/s00330-020-07362-y
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang